In the phase 3 VISION trial [34,35], conducted in patients with mCRPC previously treated with an androgen receptor pathway inhibitor (ARPI) and one or two taxane regimens, the addition of 177Lu-PSMA-617 to standard of care significantly improved both overall survival and radiographic progression-free survival compared with standard therapy alone, with a manageable safety profile characterized mainly by fatigue, anemia, xerostomia, and mild cytopenias [35,36,37,38]. Here, AR is linked to anemia (phenotype).